

ORIGINAL ARTICLE

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

M. Tempero^{1*}, D.-Y. Oh², J. Tabernero³, M. Reni⁴, E. Van Cutsem⁵, A. Hendifar⁶, D.-T. Waldschmidt⁷, N. Starling⁸, J.-B. Bachet⁹, H.-M. Chang¹⁰, J. Maurel¹¹, R. Garcia-Carbonero¹², S. Lonardi¹³, L. M. Coussens¹⁴, L. Fong¹, L. C. Tsao¹⁵, G. Cole, Jr¹⁶, D. James¹⁷ & T. Macarulla³

¹Department of Medicine, University of California San Francisco, San Francisco, USA; ²Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; ³Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UICC, CIBERONC, Barcelona, Spain; ⁴Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy; ⁵Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven & KU Leuven, Leuven, Belgium; ⁶Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, USA; ⁷Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany; ⁸Section of GI and Lymphoma Units, Department of Medicine, The Royal Marsden, London, UK; ⁹Department of Hepatogastroenterology, UPMC, Sorbonne University, Pitié Salpêtrière Hospital, APHP, Paris, France; ¹⁰Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, South Korea; ¹¹Department of Medical Oncology, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona; ¹²Department of Medical Oncology, Hospital Universitario Doce de Octubre, Imas12, UCM, CNIO, CIBERONC, Madrid, Spain; ¹³Dipartimento di Oncologia Clinica e Sperimentale, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; ¹⁴Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland; ¹⁵Department of Statistics, Pharmacyclis LLC, an AbbVie Company, Sunnyvale; ¹⁶Department of Oncology Development, Pharmacyclis LLC, an AbbVie Company, Sunnyvale; ¹⁷Department of Clinical Science, Pharmacyclis LLC, an AbbVie Company, Sunnyvale, USA



Available online 1 February 2021

Background: First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microenvironment modulation. The safety and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PDAC were evaluated.

Patients and methods: RESOLVE (NCT02436668) was a phase III, randomized, double-blind, placebo-controlled study. Patients (histologically-confirmed PDAC; stage IV diagnosis ≥ 6 weeks of randomization; Karnofsky performance score ≥ 70) were randomized to once-daily oral ibrutinib (560 mg) or placebo plus nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²). Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS); overall response rate and safety were assessed.

Results: In total, 424 patients were randomized (ibrutinib arm, $n = 211$; placebo arm, $n = 213$). Baseline characteristics were balanced across arms. After a median follow-up of 25 months, there was no significant difference in OS between ibrutinib plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine (median of 9.7 versus 10.8 months; $P = 0.3225$). PFS was shorter for ibrutinib plus nab-paclitaxel/gemcitabine compared with placebo plus nab-paclitaxel/gemcitabine (median 5.3 versus 6.0 months; $P < 0.0001$). Overall response rates were 29% and 42%, respectively ($P = 0.0058$). Patients in the ibrutinib arm had less time on treatment and received lower cumulative doses for all agents compared with the placebo arm. The most common grade ≥ 3 adverse events for ibrutinib versus placebo arms included neutropenia (24% versus 35%), peripheral sensory neuropathy (17% versus 8%), and anemia (16% versus 17%). Primary reasons for any treatment discontinuation were disease progression and adverse events.

Conclusions: Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for patients with PDAC. Safety was consistent with known profiles for these agents.

Key words: phase III, ibrutinib, metastatic pancreatic adenocarcinoma

*Correspondence to: Dr Margaret Tempero, Department of Medicine, UCSF – Mission Bay Campus/Mission Hall, 550 16th Street, 6th Floor, Box 3211, San Francisco, CA 94143, USA. Tel: +1-415-885-3846
E-mail: Margaret.Tempero@ucsf.edu (M. Tempero).

0923-7534/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

INTRODUCTION

Advanced pancreatic ductal adenocarcinoma (PDAC) is characterized by rapid disease progression and poor prognosis; the 5-year survival rate of 9%¹ marks PDAC as one of the most intractable malignancies. Gemcitabine

monotherapy represented the standard of care for first-line treatment of patients with PDAC for several years.^{2,3} Modest advances in survival came with combination therapies including fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (albumin bound paclitaxel particles). FOLFIRINOX treatment of patients with good performance status has resulted in a median overall survival (OS) of 11.1 months (versus 6.8 months, gemcitabine alone).⁴ The combination of gemcitabine plus nab-paclitaxel demonstrated a median OS of 8.5 months,³ an increase in 1.8 months versus gemcitabine alone.

There remains, however, an ongoing unmet need for novel and innovative approaches for this challenging malignancy, as current regimens are only marginally effective in extending survival and few advances have been made in more than three decades.⁵⁻⁷ Several emerging lines of evidence indicate that inhibition of the B-cell and myeloid cell signaling molecule Bruton's tyrosine kinase (BTK) may represent a novel antitumor target.⁸ Ibrutinib, a first-in-class inhibitor of BTK, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease.⁹

In preclinical models of PDAC, ibrutinib plus gemcitabine resulted in significantly reduced late-stage tumor burden and significantly increased survival by CD8+ T cell-dependent mechanisms.^{8,10} Additional mechanisms implicated in the antitumor activity of ibrutinib plus chemotherapy include: (i) changes in the tumor microenvironment, e.g. inhibition of mast cell function, decreased angiogenesis, decreased desmoplasia^{10,11}; and (ii) changes in immune profiles, e.g. alteration of Th1/Th2 transcriptional profiles¹² accompanying increased CD8+ T-cell cytotoxicity.⁸ Given these findings from PDAC models, the combination of ibrutinib plus nab-paclitaxel and gemcitabine was evaluated for first-line treatment of patients with PDAC in the phase III RESOLVE study.

PATIENTS AND METHODS

Study design

RESOLVE (PCYC-1137; [ClinicalTrials.gov](https://clinicaltrials.gov) ID NCT02436668, EudraCT Number: 2015-000905-38) was a randomized, multicenter, double-blind, placebo-controlled, phase III study comparing ibrutinib plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic PDAC. Before the randomization portion of the trial, a safety run-in of six patients (ibrutinib plus nab-paclitaxel and gemcitabine) was conducted. The results of this safety run-in were reviewed by the Data Monitoring Committee (DMC) and used to determine the ibrutinib dose for the randomized portion (560 mg). Patients were randomly assigned in a 1 : 1 fashion to receive either ibrutinib in combination with nab-paclitaxel and gemcitabine or placebo in combination with nab-paclitaxel and gemcitabine. Randomization was stratified according to Karnofsky performance status (KPS; 70-80 versus 90-100), liver metastasis (present versus

absent), and age (≤ 65 years versus > 65 years). Patients and investigators were blinded to treatment assignment. Treatment in the double-blind, randomized phase consisted of oral ibrutinib or placebo (560 mg once daily) given until disease progression or unacceptable toxicity in combination with intravenous (i.v.) nab-paclitaxel (125 mg/m²) and i.v. gemcitabine (1000 mg/m²) on day 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

The study was done in accordance with International Conference on Harmonization Guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol was approved by institutional review boards or independent ethics committees of all participating institutions. All patients provided written, informed consent.

Patients

Eligible patients were aged ≥ 18 years and had a histologically confirmed diagnosis of Stage IV PDAC within 6 weeks of randomization that was also evaluable per RECIST 1.1 guidelines¹³ with at least one measurable metastatic lesion. Additional eligibility criteria were adequate hematologic function independent of transfusion and growth factor support, adequate hepatic and renal function, KPS of ≥ 70 , and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Key exclusion criteria included patients with any previous cytotoxic chemotherapy for primary disease of PDAC, radiotherapy in the adjuvant setting within the last 6 months, and non-adenocarcinoma of the pancreas.

Study endpoints and assessments

Efficacy was assessed in the intent-to-treat (ITT) population, defined as all patients randomly assigned to each arm. The primary endpoints were OS and investigator-assessed progression-free survival (PFS). Secondary endpoints included clinical benefit response rate, overall response rate (ORR) per investigator assessment, carbohydrate antigen 19-9 (CA19-9) response, and patient-reported outcomes (PRO) via the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), measured by time until definitive deterioration (TUDD1, defined as time between randomization and first occurrence of a decrease ≥ 10 points in QLQ-C30 score without further improvement ≥ 10 points or further data due to discontinuation).¹⁴ Additional secondary endpoints were rate of venous thromboembolic events and evaluation of the safety and tolerability of ibrutinib plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine.

Response evaluations were carried out every 8 weeks and all radiologic scans were assessed for response or progression using RECIST 1.1 guidelines. Grading for best response was categorized as complete response (CR), partial response, stable disease (≥ 8 weeks), or progressive disease. Safety was assessed in the safety population, defined as all patients receiving one or more dose of any study drug. Adverse events (AEs) were graded using National Cancer Institute Common Terminology Criteria for

Adverse Events, version 4.03. An independent DMC monitored data on an ongoing basis to ensure the continuing safety of the patients enrolled/randomized in this study.

Statistical analysis

The primary endpoints OS and PFS per investigator assessment were summarized for each treatment arm using Kaplan–Meier estimates and compared using a stratified log-rank test. A two-sided family-wise type I error rate of 0.05 was used, with 0.043 allocated to the OS primary analysis and 0.007 allocated to the PFS primary analysis. All *P* values reported are nominal, with the exception of primary endpoints.

RESULTS

Patients and disposition

RESOLVE enrolled a total of 424 eligible patients beginning on 08 May 2015 (Figure 1). The ITT population consisted of 211 patients randomly assigned to receive ibrutinib plus nab-paclitaxel and gemcitabine, and 213 patients randomly assigned to receive placebo plus nab-paclitaxel and gemcitabine. In the ibrutinib plus nab-paclitaxel and gemcitabine arm, 208 patients received one or more doses of study

treatment (safety population); 2 patients (1%) were not treated due to investigator decision, and 1 patient (0.5%) was not treated due to an AE. In the placebo plus nab-paclitaxel and gemcitabine arm, 212 patients received one or more doses of study treatment (safety population); 1 patient (0.5%) was not treated due to investigator decision.

Patient demographics and disease characteristics were well balanced across study arms and are summarized in Table 1. The median age was 64.0 years (range, 32–85), and 23% of patients were aged >70 years. More men were enrolled than women (55% versus 45%, respectively) and the majority of patients were white (68%). More than two sites of metastatic disease were observed in 125 patients (30%), and liver metastases were present in 341 patients (80%) (Table 1).

The median time from stage IV diagnosis to randomization was 3.0 weeks (range, 0.1–55.0). A total of 59 patients (14%) received a prior cancer surgery (of these, *n* = 19 pancreaticoduodenectomy, *n* = 3 distal pancreatectomy with or without splenectomy), 5 patients (1%) received prior chemotherapy, and 11 patients (3%) received prior radiation therapy (Table 1). Two patients (0.5%) were enrolled who received prior chemotherapy for pancreatic




Figure 1. CONSORT flow diagram.

ITT, intent-to-treat.

Table 1. Baseline demographic and disease characteristics (intent-to-treat population)			
	Ibrutinib + nab-paclitaxel/gemcitabine (n = 211)	Placebo + nab-paclitaxel/gemcitabine (n = 213)	Total (N = 424)
Median age, years (range)	64 (32-82)	64 (32-85)	64 (32-85)
>70 years, n (%)	47 (22)	49 (23)	96 (23)
Sex, n (%)			
Male	114 (54)	121 (57)	235 (55)
Female	97 (46)	92 (43)	189 (45)
Ethnicity, n (%)			
Hispanic or Latino	7 (3)	11 (5)	18 (4)
Not Hispanic or Latino	198 (94)	197 (92)	395 (93)
Missing	6 (3)	5 (2)	11 (3)
Race, n (%)			
Asian	53 (25)	59 (28)	112 (26)
Black or African American	5 (2)	7 (3)	12 (3)
White	146 (69)	142 (67)	288 (68)
Median time from initial diagnosis to randomization, weeks (range)	3.7 (0.7-101.3)	3.7 (0.6-71.4)	3.7 (0.6-101.3)
Median time from stage IV diagnosis to randomization, weeks (range)	3.0 (0.1-55.0)	3.0 (0.4-8.1)	3.0 (0.1-55.0)
Metastatic sites of disease, n (%)			
1	79 (37)	73 (34)	152 (36)
2	85 (40)	62 (29)	147 (35)
>2	47 (22)	78 (37)	125 (29)
Liver metastases per EDC, n (%)			
Present	169 (80)	172 (81)	341 (80)
Absent	42 (20)	41 (19)	83 (20)
Baseline Karnofsky performance status per EDC, n (%)			
100	39 (18)	46 (22)	85 (20)
90	108 (51)	101 (47)	209 (49)
80	54 (26)	53 (25)	107 (25)
70	10 (5)	13 (6)	23 (5)
<70	0	0	0
Creatinine clearance (ml/min), n (%)			
<30	1 (0.5)	0	1 (0.2)
30<60	20 (9)	16 (8)	36 (8)
≥60	190 (90)	195 (92)	385 (91)
Missing	0	2 (1)	2 (0.5)
Hepatic function per NCI-ODWG classification, n (%)			
Normal	153 (73)	155 (73)	308 (73)
Mild	57 (27)	54 (25)	111 (26)
Moderate	0	2 (1)	2 (0.5)
Severe	1 (0.5)	0	1 (0.2)
Missing	0	2 (1)	2 (0.5)
Prior cancer treatment, n (%)			
Surgery	30 (14)	29 (14)	59 (14)
Chemotherapy	1 (0.5)	4 (2)	5 (1)
Radiation therapy	6 (3)	5 (2)	11 (3)

EDC, electronic data capture; NCI-ODWG, National Cancer Institute Organ Dysfunction Working Group.

Table 2. Patient disposition (safety population)		
	Ibrutinib + nab-paclitaxel/gemcitabine (n = 208)	Placebo + nab-paclitaxel/gemcitabine (n = 212)
Median time on study treatment, months (range) ^{a,b}	3.91 (0.10-24.41)	5.52 (0.07-26.32)
Median time on study, months (range) ^{b,c}	24.28 (0.30-29.70)	25.26 (0.10+31.08+)
Primary reasons for ibrutinib/placebo discontinuation, n (%)		
Disease progression	154 (74)	150 (71)
Adverse events ^d	25 (12)	26 (12)
Primary reasons for nab-paclitaxel discontinuation, n (%)		
Disease progression	117 (56)	125 (59)
Adverse events ^d	65 (31)	48 (23)
Primary reasons for gemcitabine discontinuation, n (%)		
Disease progression	147 (71)	145 (68)
Adverse events ^d	30 (14)	25 (12)

^a Time from the earliest study treatment start date to the last dose date of study treatment. Study treatment includes ibrutinib/placebo, nab-paclitaxel, or gemcitabine.

^b Time on study is based on the follow-up time of overall survival using reverse Kaplan–Meier estimates. + indicates censored observation for patient who died.

^c Ibrutinib + nab-paclitaxel/gemcitabine, n = 211; Placebo + nab-paclitaxel/gemcitabine, n = 213 (intent-to-treat population).

^d Not related to disease progression.

cancer. The primary reason for discontinuation of any drug, inclusive of placebo, was disease progression followed by AEs not related to disease progression (Table 2). The median follow-up was 24.9 months (range: 0.1+ to 31.1+).

Efficacy

The primary endpoint of OS was not significantly different for ibrutinib plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine [hazard ratio (HR) = 1.109; 95% confidence interval (CI): 0.903-1.363; $P = 0.3225$] (Figure 2A). The median OS was 9.7 months for ibrutinib plus nab-paclitaxel and gemcitabine versus 10.8 months for placebo plus nab-paclitaxel and gemcitabine. Estimated OS rates at 24 months were 9.5% for the ibrutinib plus nab-paclitaxel and gemcitabine arm and 10.5% for placebo plus nab-paclitaxel and gemcitabine. No significant differences were observed in a subgroup analysis (Supplementary Figure S1, available at <https://doi.org/10.1016/j.annonc.2021.01.070>).

PFS per investigator assessment was significantly different for ibrutinib plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine (HR = 1.564; 95% CI: 1.277-1.916; $P < 0.0001$) (Figure 2B). Median PFS times were 5.3 months for ibrutinib plus nab-paclitaxel and gemcitabine, and 6.0 months for placebo plus nab-paclitaxel and gemcitabine. Estimated PFS rates per




Figure 2. Survival analysis. Overall survival (A) and investigator-assessed progression-free survival (B) shown by treatment arm. CI, confidence interval; GCB, gemcitabine; HR, hazard ratio; Ibr, ibrutinib; nab-P, nab-paclitaxel; PBO, placebo.

investigator assessment at 18 months were 3% for ibrutinib plus nab-paclitaxel and gemcitabine versus 6% for placebo plus nab-paclitaxel and gemcitabine.

The secondary endpoint of ORR per investigator assessment was 29% (62/211) for ibrutinib plus nab-paclitaxel and gemcitabine, versus 42% (90/213) for placebo plus nab-paclitaxel and gemcitabine ($P = 0.0058$). No patient achieved a CR in the ibrutinib plus nab-paclitaxel and gemcitabine arm and 3/213 patients (1%) achieved CR in the placebo plus nab-paclitaxel and gemcitabine arm.

Percentages of patients with $\geq 60\%$ reduction in CA19-9 were 54% (113/211) for ibrutinib plus nab-paclitaxel and gemcitabine and 63% (134/213) for placebo plus nab-paclitaxel and gemcitabine. With respect to the PRO measure, median TUDD1s in QLQ-C30 score were 4.2 months (95% CI: 2.86-5.82) for patients who received ibrutinib plus nab-paclitaxel and gemcitabine and 6.1 months (95% CI: 4.86-8.21) for patients who received placebo plus nab-paclitaxel and gemcitabine. Venous thromboembolic events were reported in 8% of patients who received ibrutinib plus nab-paclitaxel and gemcitabine and in 11% of patients who received placebo plus nab-paclitaxel and gemcitabine.

Treatment exposure

The median duration of ibrutinib exposure was 3.7 months (range, 0.1-24.4) in the ibrutinib plus nab-paclitaxel and gemcitabine arm (Table 3). In the placebo plus nab-paclitaxel and gemcitabine arm, median duration of placebo exposure was 5.5 months (range, 0.1-26.1). Median treatment duration for nab-paclitaxel was shorter in the ibrutinib versus the placebo arm (3.0 months versus 4.5 months). The median number of nab-paclitaxel cycles was 4.0 versus 5.0 for the ibrutinib and placebo arms, and the median cumulative dose was lower for nab-paclitaxel in the ibrutinib versus the placebo arm (989.4 mg/m² versus 1551.2 mg/m², respectively) (Table 3). For gemcitabine, the median treatment duration was also shorter in the ibrutinib versus the placebo arm (3.5 months versus 5.1 months). Patients in the ibrutinib versus the placebo arm had lower median numbers of cycles (4.0 versus 6.0) and lower median cumulative doses (9874.5 mg/m² versus 13 822.4 mg/m², respectively) (Table 3).

Safety

Grade ≥ 3 AEs occurred in a similar proportion of patients in the ibrutinib plus nab-paclitaxel and gemcitabine arm compared with those in the placebo plus nab-paclitaxel and gemcitabine arm (86% versus 87%, respectively) (Table 4). The most common grade ≥ 3 AEs ($\geq 5\%$ of patients) were neutropenia (24%), peripheral sensory neuropathy (17%), anemia (16%), asthenia (16%), and diarrhea (14%) in the ibrutinib plus nab-paclitaxel and gemcitabine arm, and neutropenia (35%), anemia (17%), and asthenia (12%) in the placebo plus nab-paclitaxel and gemcitabine arm (Table 4). Major hemorrhage of any grade was observed in 6% of patients in each arm; grade ≥ 3 atrial fibrillation was

Table 3. Treatment exposure (safety population)

	Ibrutinib + nab-paclitaxel/gemcitabine (n = 208)	Placebo + nab-paclitaxel/gemcitabine (n = 212)
Median treatment duration, months (range)		
Ibrutinib/placebo	3.7 (0.1-24.4)	5.5 (0.1-26.1)
Nab-paclitaxel	3.0 (0.0-24.0)	4.5 (0.0-21.2)
Gemcitabine	3.5 (0.0-24.4)	5.1 (0.0-26.3)
Median total cumulative dose		
Ibrutinib/placebo, g (range)	57.3 (1.1-397.0)	78.1 (1.1-426.4)
Nab-paclitaxel, mg/m ² (range)	989.4 (122.1-7813.3)	1551.2 (116.3-4672.6)
Gemcitabine, mg/m ² (range)	9874.5 (977.1-73 061.3)	13 822.4 (930.3-79 593.6)
Median dose intensity, mg/week (range)		
Ibrutinib/placebo	3742.2 (833.0-4051.9)	3760.9 (751.2-3973.7)
Median relative dose intensity, % (range)		
Ibrutinib/placebo	96 (21-103)	96 (19-101)
Number of cycles received, median (range)		
Nab-paclitaxel	4 (1-24)	5 (1-22)
Gemcitabine	4 (1-27)	6 (1-29)

observed in 1% of ibrutinib plus nab-paclitaxel and gemcitabine-treated patients and 2% of placebo plus nab-paclitaxel and gemcitabine-treated patients.

AEs leading to discontinuation were the same in each arm (18% each). In both arms, asthenia was the most common AE leading to ibrutinib/placebo or gemcitabine discontinuation. The most common AE leading to nab-paclitaxel discontinuation was peripheral sensory neuropathy (Table 4).

DISCUSSION

In the phase III RESOLVE study, the combination of ibrutinib plus nab-paclitaxel and gemcitabine did not meet the primary endpoint of an OS or investigator-assessed PFS benefit compared with placebo plus nab-paclitaxel and gemcitabine. The rationale for investigating the combination of ibrutinib plus nab-paclitaxel and gemcitabine was based on fixed-term studies of ibrutinib plus gemcitabine in preclinical models of PDAC, wherein the combination demonstrated powerful antitumor responses by modulating the tumor microenvironment, resulting in an increase in effector CD8⁺ T cells and subsequent reduced tumor size.^{8,10} Ibrutinib combined with gemcitabine also led to mast cell inhibition, decreased angiogenesis, and reduced desmoplasia in multiple mouse models of PDAC, resulting in a significant increase in survival.^{8,10,11} Ibrutinib has demonstrated additional immunomodulatory capabilities; for example, in a mouse model of leukemia and in T cells isolated from patients with chronic lymphocytic leukemia, ibrutinib inhibited activation of Th2 cells, thus altering potential for activation of Th1 and CD8⁺ T cells.¹²

Table 4. Safety summary (safety population)

	Ibrutinib + nab-paclitaxel/ gemcitabine (n = 208)		Placebo + nab-paclitaxel/ gemcitabine (n = 212)	
	Any grade n (%)	Grade ≥3 n (%)	Any grade n (%)	Grade ≥3 n (%)
Patients with any AE, n (%)	208 (100)	178 (86)	212 (100)	184 (87)
Most common ^a AEs				
Diarrhea	148 (71)	30 (14)	111 (52)	19 (9)
Nausea	117 (56)	6 (3)	111 (52)	8 (4)
Asthenia	101 (49)	33 (16)	98 (45)	25 (12)
Pyrexia	91 (44)	6 (3)	86 (41)	8 (4)
Anemia	92 (44)	34 (16)	95 (45)	36 (17)
Alopecia	90 (43)	2 (1)	87 (41)	4 (2)
Vomiting	87 (42)	11 (5)	89 (42)	6 (3)
Decreased appetite	85 (41)	7 (3)	76 (36)	5 (2)
Fatigue	79 (38)	17 (8)	65 (31)	11 (5)
Thrombocytopenia	76 (37)	20 (10)	56 (26)	21 (10)
Neutropenia	72 (35)	50 (24)	85 (40)	74 (35)
Constipation	69 (33)	3 (1)	79 (37)	2 (1)
Peripheral sensory neuropathy	69 (33)	35 (17)	63 (30)	16 (8)
Abdominal pain	66 (32)	14 (7)	73 (34)	14 (7)
Peripheral edema	60 (29)	4 (2)	77 (36)	6 (3)
Dyspnea	26 (13)	3 (1)	43 (20)	4 (2)
Pneumonia	15 (7)	12 (6)	13 (6)	5 (2)
Most common AE leading to discontinuation of ibrutinib/ placebo, n (%)				
Asthenia		5 (2)		5 (2)
Most common AE leading to discontinuation of nab-paclitaxel, n (%)				
Peripheral sensory neuropathy		20 (10)		8 (4)
Most common AE leading to discontinuation of gemcitabine, n (%)				
Asthenia		6 (3)		4 (2)

AE, adverse event.

^a Any grade incidence ≥20% and/or grade ≥3 incidence ≥5%.

Furthermore, in a phase Ib study, patients with PDAC received a 7-day run-in treatment of ibrutinib 560 mg/day, followed by a standard regimen of gemcitabine and nab-paclitaxel plus ibrutinib.¹⁵ Blood samples and tumor tissue biopsies collected ≥5 days after the run-in period showed that treatment with ibrutinib alone led to systemic and intratumoral immunomodulatory changes in circulating lymphocytes, specifically in T and B cells and monocytes, suggesting ibrutinib's potential for an antitumor response in patients with PDAC.¹⁵

The investigational combination of ibrutinib plus nab-paclitaxel and gemcitabine in patients with PDAC did not yield a significant difference in OS between the two arms, with an HR of 1.109 ($P = 0.3225$), which did not meet the targeted HR of 0.735. The median OS reported in the phase III MPACT trial for the combination of gemcitabine and nab-paclitaxel was 8.5 months³; this was the historical control used to determine sample size in the current study. In RESOLVE, the median OS in the placebo plus nab-paclitaxel and gemcitabine arm (10.8 months) was higher than observed in the MPACT trial, but in line with the median OS observed in the western European cohort of the MPACT

trial (10.7 months).¹⁶ The median OS of 9.7 months in the ibrutinib plus nab-paclitaxel and gemcitabine arm of RESOLVE was also higher than that reported in the phase III MPACT trial,¹⁶ but lower than that in the placebo arm of RESOLVE. There were no significant differences in OS observed in the subgroup analysis. The median PFS for ibrutinib plus nab-paclitaxel and gemcitabine was 5.3 months, lower than 6.0 months as observed for placebo plus nab-paclitaxel and gemcitabine, although both values were similar to the reported 5.5 months for nab-paclitaxel and gemcitabine in the MPACT trial³ and the reported 6.4 months for FOLFIRINOX.⁴

The addition of ibrutinib to nab-paclitaxel and gemcitabine may have mitigated the ability to deliver the complete chemotherapy regimen, as patients in the ibrutinib arm had less time on treatment and received a lower cumulative dose for all agents compared with patients in the placebo arm. The differences in treatment duration and dosing of nab-paclitaxel or gemcitabine may confound our ability to interpret any potential benefit of adding ibrutinib to this chemotherapy regimen. However, in previous studies, ibrutinib has successfully been combined with other chemotherapeutic agents, in particular alkylating agents, for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.¹⁷⁻¹⁹ In the current study, there were no other notable safety findings, and safety observations were consistent with the known profiles of the individual agents.

Overall, the investigational combination of ibrutinib with nab-paclitaxel and gemcitabine in the first-line setting did not improve OS or PFS in patients with metastatic PDAC.

ACKNOWLEDGEMENTS

We thank the patients who participated in these studies, their supporters, and the investigators and clinical research staff from the study centers. This manuscript was developed with editorial support from Emily Chastain, PhD, an employee of Pharmacyclics LLC, an AbbVie Company.

FUNDING

This work was supported by Pharmacyclics LLC, an AbbVie Company (no grant number).

DISCLOSURE

MT: consultancy/advisory role with Advance Medical, AstraZeneca, Bristol-Myers Squibb (BMS), EcoR1 Capital, Elicio Therapeutics, FibroGen, Inc., GlaxoSmithKline, Immunovia, ISPEN, Karyopharm Therapeutics, Merck & Co., Inc., and Swedish Orphan Biovitrum; research funding from Celgene and Halozyne; other relationship(s) with Astellas Pharma Global Development, Inc. (DSMC). D-YO: consultancy/advisory role with ASLAN, AstraZeneca, Bayer, Genentech/Roche, Halozyne, Merck Serono, Novartis, Taiho, and Zymeworks; research funding from Array, AstraZeneca, and Eli Lilly. JT: consultancy/advisory role with Array Biopharma, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Chugai, F. Hoffmann-La Roche Ltd, Foundation Medicine, Genentech, Inc., Genmab A/S, HaliODX SAS,

Halozyne, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, Merck Sharp & Dohme (MSD), Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics LLC, an AbbVie Company, ProteoDesign SL, Rafael Pharmaceuticals, Roche Diagnostics, Sanofi, Seagen, Seattle Genetics, Servier, Symphogen, Taiho, and VCN Biosciences. MR: honoraria from Baxalta, Celgene, and Shire; consultancy/advisory role with Baxalta, Celgene, Eli Lilly, Novartis, Novocure, Pfizer, and Shire; research funding to Institution from Celgene; travel expenses from Celgene, AstraZeneca; other relationship(s) with AstraZeneca, Boston Pharmaceuticals, and Celgene. EVC: consultancy/advisory role with AstraZeneca, Bayer, BMS, Celgene, Lilly, MSD, Merck DGaA, Novartis, Roche, and Servier; research funding from Amgen, Bayer, Boehringer Ingelheim, BMS, Celgene, Ipsen, Lilly, Merck, Merck KGaA, Novartis, Roche, and Servier. AH: consultancy/advisory role with AbbVie, Ipsen, Merck, and Novartis; research funding from Ipsen. D-TW: speakers' bureau for AstraZeneca, BMS, Celgene, Eisai, Falk, Ipsen, Novartis, Roche, Servier, Shire Baxalta, and Sirtex; travel expenses from Bayer Health Pharma, Celgene, Ipsen, Novartis, and Sirtex. NS: honoraria from Eli Lilly, Merck Serono, MSD Oncology, and Pierre Fabre; consultancy/advisory role with AstraZeneca, Pfizer, and Servier; research funding from AstraZeneca, BMS, and Pfizer; travel expenses from AstraZeneca, BMS, Eli Lilly, Merck, and Roche. J-BB: honoraria from Amgen, AstraZeneca, Bayer, Celgene, Merck Serono, Mundipharma, Pierre Fabre, Roche, Sanofi, and Servier; consultancy/advisory role with Amgen, AstraZeneca, Bayer, Merck Serono, Pierre Fabre, and Servier; travel expenses from Amgen, Bayer, Celgene, Merck Serono, Roche, Sanofi, and Servier. H-MC: research funding from Astellas, Halozyne, Pharmacyclics LLC, an AbbVie Company, Senhwa Biosciences, Taiho Oncology. JM: consultancy/advisory role with Advance Medical, AstraZeneca, Bayer, Pierre-Fabre, Roche, Sanofi, Servier, Shire, and Sirtex; research funding from Amgen, Biocartis, Incyte, Merck, Nanostring, and Servier; patents, royalties, or other intellectual property with GAIS-42-patent P5020EP00. RG: honoraria from AAA, Amgen, Bayer, BMS, Ipsen, Lilly, Merck, MSD, Novartis, PharmaMar, Pfizer, Roche, and Sanofi; research funding from ARMO Biosciences, AstraZeneca, Pfizer, Novartis, Ipsen, Roche, Pharmacyclics LLC, an AbbVie Company, Boston Biomedicals, Merck, MSD, Amgen, Sanofi, Bayer, BMS, Boehringer, Sysmex, Gilead Sciences, Servier, Adacap, VCN, Lilly, PharmaMar; travel expenses from Ipsen, Merck, Novartis, and Servier. SL: consultancy/advisory role with Amgen, Lilly, Merck Serono, and Servier; research funding from Amgen and Merck Serono; speakers' bureau for BMS, Lilly, Merck Serono, Roche, and Servier. LMC: employment with Oregon Health & Science University; honoraria from Aduro Biotech, AstraZeneca, Carisma Therapeutics, Inc., Cell Signaling Technologies, CytomX Therapeutics, Inc., Jackson Laboratories, Seattle Genetics, Syndax Pharmaceuticals, Inc., Verseau Therapeutics, Inc., and Zymeworks, Inc.; consultancy/advisory role with Carisma Therapeutics Inc., Cell Signaling Technologies, CytomX Therapeutics, Inc., Syndax

Pharmaceuticals, Inc., Verseau Therapeutics, Inc., and Zymeworks, Inc.; research funding (for profit) Acerta Pharma, Deciphera Pharmaceuticals, Innate Pharma, Roche Glycart and Parker Institute for Immunotherapy, and Syndax Pharmaceuticals, Inc.; patents, royalties, or other intellectual property with Oregon Health & Science University; other relationship(s) with Reagent from Reagent support from: Acerta Pharma, LLC, Cell Signaling Technologies, Deciphera Pharmaceuticals, Genentech/Roche Glycart AG, NanoString Technologies, Inc., Plexxikon, Inc, and Syndax Pharmaceuticals. LF: research funding from AbbVie, Bavarian Nordic, BMS, Dendreon, Janssen, Merck, Roche/Genentech. GC: employment with Pharmacyclics LLC, an AbbVie Company; stock ownership in AbbVie. DJ: employment with Pharmacyclics LLC, an AbbVie Company; leadership role with Pharmacyclics LLC, an AbbVie Company; stock ownership in AbbVie; patents, royalties, or other intellectual property with Pharmacyclics LLC, an AbbVie Company. TM: consultancy/advisory role with Advance Medical HCMS, Baxter, BioLineRX Ltd, Celgene SLU, Eisai, Genzyme, Incyte, IPSEN Pharma Lab. Menarini, Lab. Servier, Lilly, QED Therapeutics, MSD, Prime Oncology EU, QED Therapeutics Inc., Sanofi-Aventis; research funding from Agios, ASLAN, AstraZeneca, Bayer, Celgene, Genentech, Hallozyme, Immunomedics, Lilly, Merimarck, Millenium, Novartis, Pfizer, Pharmacyclics LLC, an AbbVie Company, and Roche; travel expenses from Servier and Incyte. LCT has declared no conflicts of interest.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69:7-34.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol*. 1997;15:2403-2413.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*. 2013;369:1691-1703.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med*. 2011;364:1817-1825.
5. Falconi M, Mantovani W, Bettini R, et al. Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? *Dig Liver Dis*. 2003;35:421-427.
6. Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. *World J Gastroenterol*. 2014;20:14717-14725.
7. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? *Therap Adv Gastroenterol*. 2013;6:321-337.
8. Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. *Cancer Discov*. 2016;6:270-285.
9. Pharmacyclics LLC, an AbbVie Company. *IMBRUVICA® Prescribing Information*. California: Sunnyvale; 2019.
10. Masso-Valles D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. *Cancer Res*. 2015;75:1675-1681.
11. Soucek L, Buggy JJ, Kortlever R, et al. Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. *Neoplasia*. 2011;13:1093-1100.
12. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*. 2013;122:2539-2549.

13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228-247.
14. Bonnetain F, Dahan L, Maillard E, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. *Eur J Cancer*. 2010;46:2753-2762.
15. Sinha M, Betts C, Griffith M, et al. Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma (abstract P-146). *Ann Oncol*. 2019;30(suppl 4):iv40.
16. Taberero J, Kunzmann V, Scheithauer W, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. *Onco Targets Ther*. 2017;10:591-596.
17. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. *Lancet Oncol*. 2016;17:200-211.
18. Brown JR, Barrientos JC, Barr PM, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. *Blood*. 2015;125:2915-2922.
19. Davids MS, Brander DM, Kim HT, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. *Lancet Haematol*. 2019;6:e419-e428.